- Home
- AMAL vs MYGN Comparison
AMAL vs MYGN Comparison
Compare AMAL & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMAL
- MYGN
- Stock Information
- Founded
- AMAL 1923
- MYGN 1991
- Country
- AMAL United States
- MYGN United States
- Employees
- AMAL N/A
- MYGN N/A
- Industry
- AMAL Commercial Banks
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AMAL Finance
- MYGN Health Care
- Exchange
- AMAL Nasdaq
- MYGN Nasdaq
- Market Cap
- AMAL 1.1B
- MYGN 1.2B
- IPO Year
- AMAL 2018
- MYGN 1995
- Fundamental
- Price
- AMAL $32.52
- MYGN $14.18
- Analyst Decision
- AMAL Buy
- MYGN Hold
- Analyst Count
- AMAL 4
- MYGN 13
- Target Price
- AMAL $36.13
- MYGN $22.54
- AVG Volume (30 Days)
- AMAL 273.7K
- MYGN 1.2M
- Earning Date
- AMAL 01-23-2025
- MYGN 02-24-2025
- Dividend Yield
- AMAL 1.72%
- MYGN N/A
- EPS Growth
- AMAL 20.28
- MYGN N/A
- EPS
- AMAL 3.44
- MYGN N/A
- Revenue
- AMAL $304,285,000.00
- MYGN $823,600,000.00
- Revenue This Year
- AMAL N/A
- MYGN $13.60
- Revenue Next Year
- AMAL $13.99
- MYGN $3.25
- P/E Ratio
- AMAL $9.45
- MYGN N/A
- Revenue Growth
- AMAL 10.82
- MYGN 12.15
- 52 Week Low
- AMAL $21.33
- MYGN $12.04
- 52 Week High
- AMAL $38.19
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- AMAL 35.30
- MYGN 55.82
- Support Level
- AMAL $34.95
- MYGN $14.13
- Resistance Level
- AMAL $37.26
- MYGN $15.47
- Average True Range (ATR)
- AMAL 1.15
- MYGN 0.72
- MACD
- AMAL -0.19
- MYGN 0.27
- Stochastic Oscillator
- AMAL 7.06
- MYGN 61.38
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers a range of products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.